Bristol/Sanofi Plan sNDA For Plavix Acute MI Subset Indication By Year-End
This article was originally published in Pharmaceutical Approvals Monthly
Bristol-Myers Squibb and Sanofi-Aventis will file a Plavix supplemental NDA by the end of 2005 for the prevention of clinical events in patients with a history of acute ST-segment elevation myocardial infarction
You may also be interested in...
FDA approves Plavix STEMI sNDA in the midst of sponsors’ patent dispute with Apotex; Bristol-Myers Squibb/Sanofi-Aventis will likely have to compete with generic off-label prescriptions. Barr’s emergency contraceptive Plan B finally gains approval for over-the-counter sales for women age 18 and older. More approvals in brief
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011